Companies /Healthcare
Hims & Hers Health Inc - Class A
NYSE: HIMS Drug Manufacturers - Specialty & Generic
$28.07
▼ $1.31 (−4.46%) today
Markets closed · 6:34am ET

Hims & Hers (HIMS) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
14%
EPS beat rate
−272.02%
Avg. EPS surprise
Consecutive EPS misses
HIMS vs Market · 30-day return after each reportHIMSS&P 500
0%+20%+5.5%−1.2%Q2 22+13.9%+7.2%Q1 25−12.8%+3.1%Q2 25−8.4%+1.6%Q3 25+34.9%−6.2%Q4 25+7.2%+0.5%Q1 26−9.8%−0.8%Q2 26
0%+20%Q2 22Q2 25Q4 25Q2 26
HIMS EPS Trend · estimate vs actualEstimateActual
$-0.40$-0.20$0.00$0.20$-0.09$-0.10Q2 22$0.23$0.20Q1 25$0.23$0.17Q2 25$0.10$0.06Q3 25$0.04$0.08Q4 25$0.03$-0.40Q1 26$-0.05$-0.37Q2 26
$-0.40$-0.20$0.00$0.20Q2 22Q2 25Q4 25Q2 26
HIMS Revenue Trend · estimate vs actualEstimateActual
$0$300.0M$600.0M$103.9M$113.6MQ2 22$538.4M$586.0MQ1 25$552.0M$544.8MQ2 25$579.8M$599.0MQ3 25$617.2M$617.8MQ4 25$616.9M$608.1MQ1 26$730.1M$753.2MQ2 26
$0$300.0M$600.0MQ2 22Q2 25Q4 25Q2 26

How Often Does Hims & Hers Beat Earnings Estimates?

Hims & Hers beat EPS estimates in 1 of its last 7 reported quarters, and has missed 2 quarters in a row.

HIMS quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 Includes $47.5 million in legal contingencies, $28.835 million in acquisition and transaction-related costs, $4.626 million in restructuring and other related charges, and $4.223 million change in fair value of liabilities $-0.37 est. $-0.05 −640.00% $753.2M est. $730.1M +3.16%
Q1 2026 $-0.40 est. $0.03 −1,266.18% $608.1M est. $616.9M −1.42%
Q4 2025 $0.08 est. $0.04 +92.31% $617.8M est. $617.2M +0.09%
Q3 2025 $0.06 est. $0.10 −41.00% $599.0M est. $579.8M +3.30%
Q2 2025 $0.17 est. $0.23 −25.83% $544.8M est. $552.0M −1.31%
Q1 2025 $0.20 est. $0.23 −12.32% $586.0M est. $538.4M +8.84%
Q2 2022 $-0.10 est. $-0.09 −11.11% $113.6M est. $103.9M +9.32%

Figures from SEC filings and company reports. Not investment advice.